Categories
Antivaccine nonsense Medicine Quackery

Peter Götzsche is now officially antivaccine

Peter Gøtzsche, formerly leader of the Nordic Cochrane Center, has teamed with Maryanne Demasi to write a systematic review of the “harms” of COVID-19 vaccination. Besides accepting the highly dubious methodology behind one study, their preprint is yet another example of how EBM can be corrupted to promote antivax ideas.

Categories
Clinical trials Homeopathy Medicine Quackery

Why are so many clinical trials of homeopathy “positive”?

Homeopathy is The One Quackery To Rule Them All. Why, then, can homeopaths seemingly cite so many “positive” randomized clinical trials to support it?

Categories
Antivaccine nonsense Bioethics Medicine

To unblind or not to unblind COVID-19 vaccine trials?

Antivaccine alternative health tycoon Joe Mercola claims that the unblinding of participants in the clinical trials of Moderna and Pfizer COVID-19 vaccines was intended to “blow up the trials” and undermine the science, making it impossible ever to identify long term adverse events. What he’s really doing is deceptively oversimplifying complex ethical and scientific issues surrounding these trials in the middle of a deadly pandemic, all in the service of his grift.

Categories
Antivaccine nonsense Bad science Clinical trials Medicine

Update: An antivax preprint is now antivax propaganda disguised as a peer-reviewed publication in…Vaccine!

In order portray COVID-19 vaccines as dangerous, Peter Doshi has now managed to get poorly designed and performed “reanalyses” of the clinical trial data used by the FDA to grant emergency use approval of the Pfizer and Moderna vaccines published in two reputable journals, The BMJ and Vaccine? What happened?

Categories
Clinical trials Medicine Pseudoscience Quackery

Aromatase inhibitors and acupuncture in breast cancer

Four years ago, I wrote about an essentially negative study looking at whether acupuncture could alleviate joint pain caused by aromatase inhibitors, a common treatment for estrogen-sensitive breast cancer. The study’s back, and it doesn’t look any more positive.